Market Research Trends

According to FMI, the global intravenous iron drugs market was valued at $2.6 billion in 2021 and is expected to reach $6.3 billion by 2032. According to the report's findings, Intravenous Iron Drugs revenue generated by Ferric Carboxymaltose will be in high demand in the market, as they will generate the majority of revenue. According to the American Heart Association, more than 130 million adults in the United States will have cardiovascular disease by 2035. Furthermore, the Centers for Disease Control and Prevention reports that heart disease kills 0.6 million Americans each year. This data is directly related to the number of hospital admissions. Due to its expanding use, improved performance, and lower cost, the Ferric Carboxymaltose (FCM) segment led the market for intravenous iron medicines in 2021, with nearly 50% revenue share. It is a dextran-free parenteral iron medication recommended for the rapid and high-dose replacement of depleted iron reserves. This medication...

Global  Intravenous Iron Drugs Market  was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds Fact.MR in a recent market survey. As per the findings of the report, Intravenous Iron Drugs revenue through Ferric Carboxymaltose will garner significant demand in the market as the bulk of revenue will be generated through them. The American Heart Association predicts that by 2035, more than 130 million adults in the United States will have cardiovascular disease. In addition, the Centers for Disease Control and Prevention reports that 0.6 million Americans die each year from heart disease. This information leads directly to the number of hospital admissions. The Ferric Carboxymaltose (FCM) segment led the market for intravenous iron medicines in 2021, with nearly 50% revenue share due to its expanding use, improved performance, and lower cost. It is a parenteral iron medication devoid of dextran which is suggested for the quick and high-dose replace...